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Chronic inﬂammation associated with cigarette smoke fosters malignant transformation and tumor cell proliferation and
promotes certain nonneoplastic pulmonary diseases. The question arises as to whether chronic inﬂammationand/or colonization
of the airway can be attributed, at least in part, to tobacco-associated microbes (bacteria, fungi, and spores) and/or microbial
toxins(endotoxinsand mycotoxins)in tobacco.To address this question,a literature search ofdocuments invarious databaseswas
performed. The databases included PubMed, Legacy Tobacco Documents Library, and US Patents. This investigation documents
that tobacco companies have identiﬁed and quantiﬁed bacteria, fungi, and microbial toxins at harvest, throughout fermentation,
and during storage. Also characterized was the microbial ﬂora of diverse smoking and smokeless tobacco articles. Evidence-
based health concerns expressed in investigations of microbes and microbial toxins in cigarettes, cigarette smoke, and smokeless
tobaccoproducts are reasonable;theywarrantreview byregulatory authoritiesand,ifnecessary, additionalinvestigationto address
scientiﬁc gaps.
1.Introduction:Chemicaland Biological
Componentsof Tobaccoand Smoke
For many years, scientists have undertaken studies to deﬁne
the chemical composition of green tobacco leaf, cured-
fermented-stored tobacco leaf, and tobacco smoke with the
intent of identifying chemicals that may pose a signiﬁcant
health risk [1–4]. An illustration has been prepared of the
annual increase, from 1954 to 2005, in the total number
of tobacco smoke chemicals that have been identiﬁed [4].
Today, there is a consensus of opinion that cigarette smoke
consists of at least 5,300 diﬀerent chemicals [4]. These
chemicals are present in the complex aerosol that consists of
a heterogeneous mixture of gas- (vapor-) phase and particu-
late- (“tar-”) phase components [1–4].
Detailedlistings ofthechemicalsinmainstream andside-
stream tobacco smoke are available, and an assessment of
theirpropensity forharmhasbeen presented;apartial listing
of references is included [1–4]. Most of the chemicals,
toxicants, and carcinogens in tobacco smoke arise from the
burning (pyrolysis) of the tobacco [1, 2, 4]. The potential for
harm has also been studied for chemicals that do not arise
from the burning of tobacco. The chemicals include metallic
and nonmetallic elements, isotopes, and salts [1, 2, 4]. In
addition,pesticidesandotherintactagrochemicalshavebeen
identiﬁed in tobacco smoke [1, 2, 4]. Also included in this
tabulation of chemicals in smoke are menthol and ﬂavorants
[4].
In 1985, Hoﬀmann and coworkers, who had studied the
chemical composition of tobacco smoke for many years, be-
gan formulating a list of chemicals that were designated as
biologically active, carcinogenic, cocarcinogenic, or tumor-
genic, reviewed previously in [4]. The tabulation was revised
and became the basis for the list of “Hoﬀmann Analytes”
[4]. In 1985, diﬀerent working groups met to identify those
chemicals in tobacco smoke that are most likely to be2 Journal of Oncology
carcinogenic to humans as deﬁned by criteria of the In-
ternational Association for Research on Cancer (IARC), an
intergovernmental agency forming part of the World Health
Organization, and by the US National Toxicology Program
(NTP) [1, 2, 4].
2.The ChangingCigarette
The identiﬁcation, classiﬁcation, and concentration of the
variouschemicalsin cigarettesmokehavebeenchallengedby
changes in the design of cigarettes. A comprehensive review
of “The Changing Cigarette” was published by D. Hoﬀmann
and I. Hoﬀmann in 1997 [5].
Subsequently, other investigators addressed changes in
cigarettes and their potential for risk [6–12]. By way of
example, a partial tabulation of changes in cigarette includes
(a) increased cigarette length (85mm king sized and extra
long “120’s”) and, for some brands, reduced circumference
(23mm “slim” cigarettes), (b) variation in the blend of nat-
ural tobaccos of diverse types, country of origin, and curing
processes,relativepercenttobaccoleaf(lamina)versustobac-
co ribs/stems, and tobacco weight per rod, (c) incorporation
of manmade tobacco, sometimes referred to as reconstituted
or “sheet” tobacco, (d) introduction of additives to the to-
bacco (casings) that include diverse ﬂavorings (licorice and
honey),humectants toretain tobaccomoisture, andmenthol
to ameliorate smoke irritation and promote smoking accep-
tance by youngsters and “starters” (e) addition of ammonia,
tofacilitate“freebasing” thenicotine toenhancethepharma-
cological eﬀect (impact), (f) application of diverse glues and
printingink,(g)conﬁgurationofdiversecigaretteﬁltermate-
rials (cellulose acetate, paper, or combination of both), (h)
alteration of ﬁlters with charcoal and schemes whether the
carbon was dispersed throughout the ﬁlter plug or retained
in a ﬁlter cavity, (i) variation in ﬁlter design (ﬁlter length,
ﬁber packing/crimping, ﬁber density, and ﬁlter ventilation)
to eﬀect tar delivery (full ﬂavor cigarettes versus ultralight
low-tar cigarettes), (j) paper type, paper porosity, with burn
accelerators to promote burning, or with modiﬁcations to
reduce the propensity for sustained burning and aﬀect a “ﬁre
safe” designation, and (k) diverse methodologies to reduce
“tar” and nicotine yields in mainstream smoke of cigarettes
that have been smoked mechanically [6–12].
The topic of “The Changing Cigarette” has been addres-
sed and summarized in a recent report of the Surgeon Gen-
eral entitled “How Tobacco Smoke Causes Disease” [13].
A review of the scientiﬁc and medical literature has shown
that (a) changing cigarette designs over the last ﬁve decades,
including the introduction of cigarette ﬁlters and low-tar
cigarettes,havenotreducedoveralldiseaseriskamongsmok-
ers and may have hindered prevention and cessation eﬀorts,
(b) there is insuﬃcient evidence that novel tobacco products
reduce individual and population health risks, and (c) the
introduction of novel tobacco products that are marketed as
reduced-risk cigarettes may encourage tobacco use among
youngsters. These changes have challenged tobacco policy
and regulation [13].
3.Tobacco and HarmAssociatedwithMicrobes
Our review of the aforementioned writings [1–4]a n dm a n y
other related reports, addressing chemicals in tobacco smoke
of cigarettes have shown that the writings do not address
the propensity for harm that may be associated with micro-
bial elements of smokeless and smoking tobacco articles.
A partial listing of tobacco-associated microbial elements
include bacteria (Gram positive and Gram negative), bacte-
rial spores, fungi (yeast and mold), fungal spores, cell wall
components (certain glucans and ﬂagellum), and diverse
microbial toxins that include exotoxins and endotoxins.
Examples of bacterial-derived toxins include endotoxins
(lipopolysaccharide, LPS; inﬂammatory factor) and fungal-
derived mycotoxins (aﬂatoxins, AF type B1; human carcino-
gen) [1–4].
There exists today a concern of the potential health risks
associated with diverse microbial elements that are known
to exist in smoking and smokeless tobacco products that
are currently being marketed. This subject has not been
addressed in the context of national tobacco control policy
or regulatory authorities.
Harm is to be recognized as persistent or chronic inﬂam-
mation. Inﬂammation is mediated by diﬀerent leukocyte
subsets and diﬀerent secreted factors (Figure 1). Inﬂamma-
tion not only establishes a microenvironment that fosters
the malignant transformation and tumor growth but also
promotes microbial colonization.
4.ResearchObjectives
The goal of this paper is to proﬁle the scientiﬁc and medical
literature addressing microbes in tobacco with the intent to
determine whether there is suﬃcient evidence to warrant
additional investigations to assess propensity for human
harm. The impetus for undertaking this work was derived
in part from the fact that several teams of investigators,
including our own, have published observations during the
last few years that suggest microbial elements maybe harmful
to tobacco users.
Notable in a ﬁrst analysis of the literature on the micro-
biology of tobacco we discovered that there were few recent
reports (1990 to 2010) in peer-reviewed, mainstream, scien-
tiﬁc and medical journals by scientists of tobacco companies.
By way of example, Philip Morris has contracted the Life
Science Research Oﬃce, Inc., (LSRO, Bethesda, MD), to
identify methods to evaluate tobacco products and with a
particular focus on identifying research schemes and assays
for assessing reduced-risk tobaccoarticles [14].Three mono-
graphs published by LSRO in 2007 detailed the chemicals
to be assayed and recommended procedures. The subject
of microbial ﬂora and microbial toxins was not addressed,
nor were schemes and methodologies for the assessment of
tobacco associated bacteria, mold, or microbial toxins [14].
Therefore, the question arose as to whether the issue of
health risks associated with microbial elements in smokeless
and smoking tobacco was not investigated by laboratory
scientists working at the tobacco companies or whether the
subject was studied and the information withheld as privateJournal of Oncology 3
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Figure 1: A schematic view of an alveolus that depicts the eﬀect of
inhaled tobacco smoke on the terminal (respiratory) structure of
the lung. Particulate matter “Tar” in tobacco smoke is inhaled deep
into the lung where it is recognized by macrophages. The macro-
phages arise from the blood monocytes that migrate into the lung
where they undergo diﬀerentiation and maturation. Macrophage
phagocytosis of the chemical-rich “Tar” evokes the production
of diverse proinﬂammatory mediators (for details, see Figure 1).
Macrophages have toll-like receptors (TLR) that recognize diverse
m i c r o b e sa n dt o x i n s( L P Si sr e c o g n i z e db yT L R - 4 ) .S h o w ni nt h i s
illustration is the production of ﬁve proinﬂammatory cytokines:
tumor necrosis factor, type alpha (TNFα), interleukin 1-beta (IL-
1β), leukemia inhibitory factor (LIF), oncostatin M (OSM), and
Interleukin-4 (IL-4). These soluble factors interact with other cells
of the lung, and the response of these cells is thought to accelerate,
amplify,andprolongpulmonaryinﬂammation.Thetargetcellsmay
include T cells. The T cell that is depicted herein is representative of
many diﬀerent T cell subsets, including T helper cell subsets Th1,
Th2, and Th17. Type I epithelial cells are the major cells lining
the alveolar space, and facilitating O2/CO2. The type I cells are
spread out and cover about 90 to 95% of the alveolar surface.
The type II cells form only 5 to 10% of the surface but produce
surfactantproteins.Polymorphonuclearleukocytes (PMN)mediate
inﬂammation in multiple ways, including the production of an
oxidative burst. Dendritic cells (DC) are professional antigen-
presenting cells; they also mediate inﬂammation.
and conﬁdential. The paucity of the literature on health risks
associated with microbes in smokeless and smoking tobacco
is to be contrasted to the numerous reports by tobaccoscien-
tists researching other health-related issues, such as potential
reduced-risk exposure tobacco products (PREPS) [15].
5.Perspectiveand Limitations
The authors are immunologists and have an active research
interest in addressing tobacco-associated chronic pulmonary
inﬂammation. It is acknowledged that immunological re-
sponses and inﬂammation would not be a primary inter-
est by other investigators whose primary interests are
in the disciplines of microbiology/metagenomics, aerosol-
associated inhalation toxicology, infectious diseases, and
clinical pathology (oral and lung). Also, the work presented
herein is limited in scope. The authors retrieved numerous
documents from databases, but space restrictions permit cit-
ing but a few of the writings. Also, many of the writings were
internal documents and were not subjected to peer-review.
Some documents cited are old and are addressed herein to
provide a historical perspective. Lastly, the documents are
fragmented and it is recognized that conﬂicting ﬁndings
and interpretations may be presented by competing tobacco
companies.
6.LiteratureSearch
A computer-based structured search of the literature was
conducted. The study scheme included a search of the lit-
erature from PubMed (http://www.ncbi.nlm.nih.gov/pub-
med) and Scopus (http://www.scopus.com/home.url). Also,
included was a search of Google (http://www.google.com/).
A search was also made of patents in the database
of the US Patent and Trade Oﬃce (http://www.uspto.gov/).
In addition, searches were made for documents that were
released by the tobacco companies and made public as a
consequence of the tobacco Master Settlement Agreement.
To this end, we searched database records of over 11 million
documents in the digital archive that were established and
which are maintained currently at the University of Califor-
nia, San Francisco (http://legacy.library.ucsf.edu/). We also
searched the database from Tobacco Documents (http://to-
baccodocuments.org/).
The searches were performed using conventional tele-
gram-style search short-string text formulations with Bool-
ean operatorsas described in PubMed. Illustrative key search
w o r d sw e r eb a c t e r i a ,m o l d ,f u n g i ,y e a s t ,t o b a c c o ,s m o k e ,
endotoxin,mycotoxin,cured,fermented,lipopolysaccharide,
aﬂatoxin, and microbiology. We also used unique search
words, such as author’s name, project designation, report
codes, cigarette brands, and Bates number. The references
cited in the retrieved literature were reviewed to identify
other topic-speciﬁc writings Table 1.
7.Tobacco-AssociatedChronic Inﬂammation
Chronic inﬂammation is associated with malignant trans-
formation, tumor growth, and, possibly, tumor metastasis,
reviewed in [44–52]. Examples of the association of cancer
with chronic inﬂammation include (a) lung cancer and
cigarette smoke (aerosol), (b) malignant mesothelioma and
asbestos (ﬁbers),(c)stomachcancerand H.Pylori( b a ct e ri a ) ,
(d) malignant melanoma and ultraviolet sun light (irradia-
tion),(e)livercancer and aﬂatoxin (mycotoxin),and (f)can-
cer of the uterine cervix and human papilloma virus. Thus,
malignancy at diverse body sites, and of various tissues, is
associated with chronic inﬂammation provoked by assorted4 Journal of Oncology
Table 1: History of investigations of microbes and microbial toxins in tobacco and tobacco products.
1896 [16] Results are reported for studies that were undertaken to characterize the microbes of tobacco before and during
tobacco fermentation.
1899 [17]
German bacteriologist H. E. Suchsland announces that the delicate aroma and subtle shades of ﬂavorwhich aﬀect the
palate of the smoker are not due to the tobacco but are attributed to the microbes which aid in the process of tobacco
fermentation. A patent based upon this observation was submitted, presumably to improve the poor quality of
German tobacco by adding to the harvested tobacco leaves bacteria that he had isolated and grown in his laboratory
from high-quality West Indian tobacco.
1954 [18] The microbial degradation of nicotine and nicotinic acid was reported. The morphological and physiological
properties of the nicotine-decomposing bacteria were also described.
1955 [19]
W. C. Flanders of R. J. Reynolds Tobacco Company issues a 70-page report of a three-year study to determine if the
number of microorganisms (bacteria and mold) changed appreciably during aging. Experiments were also
conducted to determine if the recorded changes in the microbes follow the changes in the chemical components of
tobaccos. These studies were continued and extended for several years.
1957 [20]
Pseudomonas aeruginosa and other potentially pathogenic fungi and bacteria were identiﬁed in snuﬀ. Similar
microbial isolates from a patient was the basis for the physician to theorize that some of the snuﬀ-derived microbes
may be responsible in part for chronic bronchitis.
1958 [21, 22]
The results of studies were reported that had been undertaken to characterize the deposition of cigarette smoke
particles and debris released from the cigarette ﬁlter into the human respiratory tract. Popular brand cigarettes were
smoked mechanically and in a manner to reﬂect normalsmokingbehavior. The studies documented that tobacco
ﬂakes and ﬁne tobacco leaf debris were released into mainstream smokefrom the cigarette ﬁlter of all brands that
were tested (Tareyton, Winston, Kent, L&M, Marlboro, and Viceroy). The tobacco ﬂakes and other particulates (ﬁlter
ﬁbers and carbon from charcoal ﬁlters) were studied by light and electron microscopy.
1966 [23] Toxic fungi were identiﬁed in tobaccos.
1967 [24, 25] Comparative studies were preformed for microbiologicalactivity in the smoke of popular brand nonﬁltered and
ﬁltered cigarettes that had been “cold smoked” or lit. Viable bacteria were found in the smokeof all cigarettes tested.
1972 [26]
The tobacco from diﬀerent popular brands of cigarettes was analyzed for bacteria. The number of bacteria was
determined on “our own” (Philip Morris) and competitive cigarette ﬁllers. This test was run for several months and
each month Viceroy, Brown & Williamson’s product, always showed the lowest degree of “contaminant.”The
diﬀerence between the brands was statisticallysigniﬁcant. Brands tested included Salem, Pall Mall, Chesterﬁeld, Kool,
Kent, Viceroy, Winston, and Marlboro. The number of bacteria on Marlboro were “too numerous to count.”
1972 [27]
A 189-page report was prepared by investigators at the Brown & WilliamsonTobacco Company that presents
methods for the microbiologicalexamination of tobacco and tobacco products. The writings include the description
of techniques for the quantitative determination of bacteria and fungi and methods for the isolation of potentially
human pathogenic microorganisms including Coliform bacteria. Also identiﬁed were Staphylococcus aureus,
Enterococci, Pseudomonas, Clostridium,a n dAspergillus.
1972 [28]
A 52-page report that describes a “contact plate method” in which a whole cigarette is rolled over the surface of the
nutrient agar dish. Viable microbes that are transferred from the cigarette to the plate are illustrated. Presumably, the
intent of the assaywas to measure the growth of microbes that would be transferred from the cigarette paper to the
hand of the smoker. Other studies showed the growth of microbes from a natural wrapper of a cigar. Also, culture
methods were established for testing for coliform bacteria and for counting viable fungi in tobacco.
1972 [29]
A 346-page in-house document is produced by the British-American Tobacco Company entitled “Methods for the
Microbiological Examinationof Tobacco and Tobacco Products.” The authors describe the “Public Health Aspects”
of smokingand smokeless tobacco products. They note that “[T]he detection of micro-organisms of health
signiﬁcance in tobacco products must be expected to be regarded as undesirable or even unacceptable by public
agencies, regardless of whether there is proof of the signiﬁcance in initiating or spreading infection in man.
Therefore, it is suggested that tobacco products should be substantially free, or contain only minimal numbers, of
micro-organisms of potential health signiﬁcance to man which could conceivably occur on tobacco...” Suggested
standards are presented for tobacco products for various bacteria and fungi, and standards that had been established
for food products (ﬁsh, sausage, meat pies, cream yogurt, soft cheese, and pasteurized milk).
1991 [30]
Philip Morris characterizes the microbial population on Marlboro tobaccos throughout the processing line. Five
diﬀerent Marlboro Make-Your-Own tobaccos with various anti-microbial preservatives were evaluated
microbiologically for mold and bacteria over time. The microﬂora of Marlboro raw and tobacco blends were deﬁned
for burley, oriental, ﬂue-cured, and other tobacco types.Journal of Oncology 5
Table 1: Continued.
1992 [31] Bacillus spores were identiﬁed in chewing tobacco sold in the USA. Broth of the culture microbes evoked plasma
exudation from the oral mucosa when tested using a hamster cheek pouch assay.
1995 [32] In an oral presentation, Hasday describes for the ﬁrst time the presence of endotoxin in cigarette smoke.
1990 [33] Scientist from Imperial tobacco (Canada) report the development of an easy-to-search database on the microbes
associated with tobacco.
1999 [34] Bacterial endotoxin was identiﬁed as an active component of cigarette smoke.
2004 [35] A US Patent was awarded for a method and system for assayand removal of harmful toxins during the processing of
tobacco products.
2004 [36]
Microbiologists in Sweden used a mass-spectrophotometry-based assay to document that tobacco smokingincreased
dramatically the air concentrations of endotoxin (LPS). The authors note that smoke-derived LPS may be a health
risk factor associated with environmental tobacco smoke.
2004 [37]
A US Patent was assigned to Philip Morris for an “antibacterial lavage” method to treat tobacco leaves so as to
eliminate or reduce bacterial endotoxins (LPS) and tobacco-speciﬁc nitrosamines that are formed during the curing
process. Bacteria found on tobacco leaves were reported to be primarily Gram-negative bacteria, including
pseudomonades and enterobacters. In the awarded patent, Hempling notes that bacterial endotoxins can remain as a
residue on the tobacco even after the bacteria have been destroyed.
2004 [36] The microbiological compositionof tobacco products was deﬁned using culture and chemical analysis.Tobacco
smoke was analyzed chemically, and LPS was measured for tobacco leaves and cigarette tobacco.
2005 [38]
US Military publishes a report of an investigation that documents bacterial species diversity of varying brands of
cigarettes made in the Middle East that were thought to be associated with illnesses of American soldiers deployed in
Operation Iraqi Freedom.
2006 [39] Cigarette smokewas identiﬁed as the source of elevated levels of endotoxin (LPS) found in indoor air.
2007 [40]
Identiﬁcation of microﬂora on tobacco using culture-independent methods based on the ampliﬁcation of microbial
16S rDNA sequences directly from the leaf surfaces. The investigators discovered also that three of ﬁve dominant
bacterial species on the tobacco could not be cultivated.
2008 [41]
The microbiological compositionof tobacco products was deﬁned using culture and chemical analysis (of tobacco
leaves) or chemical analysis only (tobacco and tobacco smoke).Mesophilic bacteria dominated among the bacteria in
both fresh and cured tobacco leaves; however, a wide range of other bacteria, including Gram-negative bacteria, and
fungi were delineated. Microbial ﬂora was compared in studies of tobacco from cigarettes from diﬀerent countries.
LPS was also measured.
2008 [42]
Bacteria grown from a single ﬂake of tobacco from all brands of smoking(cigarette, cigar, and pipe) and smokeless
(snus, snuﬀ, and long cut) tobacco products. In many instances, the bacteria from the tobacco caused hemolysis of
blood in blood agar and liquid broth cultures.
2010 [43]
Twenty-seven species of bacteria were identiﬁed in an analysis of both unaged tobacco and ﬂue-cured tobacco by
16SrRNA sequence analysis.More species (N = 23) were identiﬁed from the unaged ﬂue-cured tobacco leaves than
in the aging leaves (N = 15 species).
2010 [43]
Fifteen classes of bacteria and a broad range of potentially pathogenic organisms were detected in all cigarette
samples studied. In greater than 90% of the tobacco samples, the investigators identiﬁed Acinetobacter, Bacillus,
Burkholderia, Clostridium, Klebsiella, Pseudomonas aeruginosa,a n dSerratia. The bacteria were identiﬁed using a
16SrRNA-based taxonomicmicroarray. Cloning and sequencing were used to evaluate total bacterial diversity of
four brands of cigarettes. Previous studies have shown that smoking was associated with colonizationby pathogenic
bacteria and an increased risk of lung infection. This study, however, was the ﬁrst to show that cigarettes themselves
could be the source of exposure to a wide array of potentially pathogenic microbes.
items that include smoke, bacteria, ﬁbers, irradiation, toxins,
and viruses.
8.CigaretteSmoke,ChronicInﬂammation,
and Impaired Immunity
Cigarette smoke is known toinducechronic inﬂammation of
the lung [53–60]. More recently, a substantial body of infor-
mation has been obtained to suggest that long-term cigarette
smoking may not only have an adverse eﬀect of systemic im-
munity but also skews both innate and adaptive immune
responses [61–65].
9.StudyRationale:Evidence-BasedHealth
RisksofTobacco-AssociatedMicrobes
Concern has been expressed by many investigators that mi-
croorganisms oncuredtobaccomightrepresentahealthrisk.6 Journal of Oncology
By way of example, in 1968, Wood [66], a scientist at the
British American Tobacco Company, wrote a 37-page report
addressing the possible transfer of viable microorganisms
into mainstream smoke. In this internal document, he notes
that cured tobacco, of various types, has long been known
to contain bacterial spores. Likewise, Wood [66]a n do t h e r s
[23] have addressed the possibility that tobacco-associated
moldmay also represent a healthhazard tosmokers. Support
for this concern was derived in part from a paper published
in Science by Forgacs and Carll two years previously in
which they reported the identiﬁcation of toxic fungi in
tobacco [23]. In the Science paper, the investigators exposed
mice to smoke from fungally contaminated hay. The mice
developed pulmonary emphysema and other pathological
conditions; in contrast, mice exposed to smoke from sterile,
uninoculated hay remained normal clinically. In a letter to
the Associate Scientiﬁc Director of the Council for Tobacco
Research, dated 1964, Forgacs, with more than 16 years
of research experience as a mycologist, states that he had
examined mycologically a number of tobacco products,
including cigarettes that had been purchased on the open
market [67]. Forgacs observed that the tobacco of all
cigarettes contained fungal mycelia and spores [67]. In part,
the origin of his health concern is based upon the knowl-
edge of (a) widespread fungal contamination of tobacco
products, (b) heat stability of the mycotoxins; (c) known
animal toxicity, (d) reasonable assumption that some of the
fungi are carcinogenic, and (e) potency at low doses, see also
[68].
Wood argues that
“[W]hile it is quite impossible to deduce, from
this (mouse) experiment, the likely eﬀect of
smoke from a cigarette containing fungally
contaminated tobacco, the implications are suf-
ﬁciently important to warrant some considera-
tionoftherolewhichmicro-organismsmayplay
with regard to smoke toxicity. For instance, it is
possible that viable spores might be transferred
to mainstream smoke and thus enter the lungs;
pathogenic species, even in small numbers,
could clearly have harmful eﬀects, while very
large number of otherwise harmless micro-
organisms might lead to a signiﬁcant concen-
tration of genetic material. Alternatively, during
the vegetativestageoftheirresidenceontobacco
the micro-organisms might produce toxins
which couldtransfer directtosmokeormetabo-
lites which on burning could give toxic smoke
constituents.”
The report by Wood also describes some preliminary
experiments which were undertaken to show whether bacte-
rial or fungal spores could transfer into tobacco smoke. Two
schemes were used to trap the cigarette smoke; these were
a test tube bubbler and a micropore ﬁlter. These samples
from the bubbler and the ﬁlter were tested for the growth of
microorganisms. Growth of microbes was observed; how-
ever, technical problems were encountered including poor
reproducibility and smoke toxicity. The results were incon-
clusive. Our search for subsequent studies by Wood address-
ing this subject failed to identify subsequent experiments or
published reports. Studies by Slutzker et al. were negative
[69]. In 1967, Curby reported to The Council for Tobacco
Research the results of comparative studies that he had
undertaken to determine the microbiological activity in the
smoke from ﬁlter and nonﬁlter cigarettes. Diﬀerent popular
brands of cigarettes were obtained from local vendors in
Brookline, Mass, USA. Comparative analyses were made
of bacteria released from cigarettes that had been “cold
smoked” (not lit) or smoked in the usual manner (lit). The
tobacco smoke collection system was tested for sterility by
means of conventional microbiology culture procedure and
by means of electronic analyses of particle size and number.
Viable bacteria were identiﬁed in the smoke from all ciga-
rettes tested. The number of liberated organisms was much
greater when the cigarette was burning [24, 25].
Before proﬁling more recent studies, a brief overview is
warranted of what many internal documents of the tobacco
industry have entitled the “Microbiology of Tobacco.”
10.Microbiology ofTobacco
The “Microbiology of Tobacco” has been the focus of many
studies. It was not surprising to learn from our paper that
most of all the major tobacco companies have studied this
issue for many years. Listed below are varying topics ad-
dressing bacteria, mold, and mycotoxins in tobacco and ref-
erences
(a) chemical and microbiological changes during curing
[16, 19, 70–75],
(b) bacteria in cigarettes; product comparison (also, see
below) [17, 76–79],
(c) databases of tobacco microbes [33, 40, 80],
(d) tobacco microbe control [81],
(e) microﬂora community of tobacco [82–88],
(f) quantitative studies of tobacco microﬂora [89–91],
(g) growth of mold in stored tobacco [26, 92],
(h) growth of Aspergillus from tobacco [93–95],
(i) microbial degradation of nicotine [18, 96],
(j) examination of cigarettes from mold-damaged and
nondamaged tobacco [97],
(k) isolation of viable fungi from snuﬀ [98],
(l) sterilization/treatment to remove NNK [37, 99–105],
(m) removal of harmful toxins on tobacco [35, 95],
(n) inhibiting mycotoxin production [106],
(o) microbiology of cigarettes, pipes, cigars, and snuﬀ
[27–30, 107–111].
From about the early 1970s, extensive research was con-
ductedontheMicrobiologyofTobacco.Manyreportsreﬂected
the interest of the major tobacco companies. These stud-
ies sought to identify diﬀerent bacteria and molds and toJournal of Oncology 7
count the number of colony-forming units (CFU) during
processing. The number of bacteria and molds present in
green,freshly harvested tobaccowascompared tothat ofvar-
ious stages of curing, fermentation, and long-term storage.
In many cases, more than one million bacteria were found in
a gram of tobacco (a 100mm cigarette has about 0.9grams
of tobacco). Comparative studies included various types of
tobacco (Bright and Burley) and diﬀerent curing methods
(ﬁeld versus ﬂue cured). In these studies, proﬁles were
established for leaves of the diﬀerent types of tobacco that
had been picked from various positions of the plant. Diverse
environmentalconditionswereevaluated,andtheseincluded
variations in temperature and moisture. Analyses were made
of the number of bacteria in popular brand cigarettes. In
many instances, the number of bacteria of a particular
c om pa n y ’ sbra n dw a sc om pa r edt obra n dsm a r k et edb yc om -
petitors. In addition to cigarettes, studies were performed
for cigars and snuﬀ.C o n s i d e r a b l ee ﬀort was devoted to
deﬁning procedures for the sterilization of tobacco to reduce
or prevent the growth of mold. The methods used included
(a) washing methods using various solutions (bleach), (b)
irradiation with microwave, ultraviolet light, and gamma
radiation, (c) exposure to various gases, and (d) treatment
with diﬀerent antibacterial and antifungal agents (antibi-
otics). One scheme was to destroy all of the bacteria on
freshly harvested green tobacco leaves and then seed the
leavesforfermentationusingselectedcoloniesfromin-house
batch-scale production. Quality control of the tobacco was
important as high levels of mold produced an unacceptable
“oﬀ-taste.”
11.PathogenicBacteriaofChewingTobacco
Studies have been conducted by investigators of the tobacco
industry (see above) and health community to address the
potential of bacteria, molds, yeast, and microbial toxins
found in diﬀerent types of smokeless tobacco (snuﬀ,s n u s ,
and long cut) [20, 26, 31, 43, 112, 113].
In 1951, Dynert published in The New England Journal of
Medicine a case report of a patient with chronic bronchitis.
Pseudomonas aeruginosa, often colonized in COPD patients,
and a few colonies of Staphylococcus aureus were identiﬁed
in bacteriological examinations of the subject’s sputum [20].
The patient used snuﬀ, and it was theorized that the snuﬀ
may have been the source of the pathogens. A study was
thenundertakenof22samplesofpreviouslyunopenedpacks
of snuﬀ. The following microorganisms were grown from
more than 50% of the snuﬀ samples: Bacillus rubitilles,
Staphylococcus aureus (coagulase positive), Staphylococcus
albus (coagulase positive), Pseudomonas aeruginosa, Staphy-
lococcusaureus(coagulasenegative),andStaphylococcusalbus
(coagulase negative).
In 1991, Varma reported the isolation of nine species of
Aspergillus in stored leaves of chewing tobacco [112]. Ap-
proximately 18 of the Aspergilli were found to be mycotoxi-
genic.All aﬂatoxigenic strains of A. ﬂavusproduced aﬂatoxin
B1. Patulin and ochratoxin were produced by A. ochraceus.
Sterigmatocystin was produced by three diﬀerent strains.
Warke [103]studiedthe microbiologicalqualityofchew-
able, often sweet, tobacco mixes known as “Gutka” used by
millions of children and adults in India where it is made
and often exported. Of the 15 samples studied, all contained
aﬂatoxins B1,B 2,a n dG 2. Samples exposed to 60Co radiation
displayed a marked reduction of viable CFU. Sterilization
of tobacco in the manufacturing has been described in US
Patents [105].
In 1992, Rubenstein reported the identiﬁcation of large
number (>106CFU) of a Bacillus species in chewing tobacco
sold in the USA [31]. Supernatants of the cultured bacteria
evoked a plasma exudate in studies in which the supernatant
was instilled into an intact hamster cheek pouch.
12.PathogenicBacteriaof Cigarettes
Somebacteriagrowinuniquemicroenvironments, andsome
are diﬃcult to grow using traditional broth- and agar-based
methods. This technical diﬃc u l t ym a ya l s oa p p l yt og r o w i n g
bacteria that have adapted to unique conditions that develop
during the curing and fermentation of tobacco. Accordingly,
it is believed that conventional methods may not accurately
deﬁne the microﬂora of diverse tobacco products [43, 113].
Consequently, there may be an incomplete understanding of
thebacterial diversityin thetobaccoofcigarettes and also the
impact these microbes and microbial toxins may impose on
the smoker [113].
Recently, the bacterial metagenomic of cigarettes were
characterized using a16SrRNA-basedtaxonomicmicroassay
as well as traditional cloning and sequencing methods.
The brands included Camel, Marlboro, Kool, and Lucky
Strike. The results of this study showed that the number of
microorganisms in cigarettes may be as vast as the number of
chemicals in these products. Fifteen classes of bacteria were
identiﬁed [113]. Particularly noteworthy was the identiﬁca-
tion of a broad range of potentially pathogenic microorgan-
isms detected. More than 90% of the tobacco samples from
the cigarettes contained Actinetobacter, Bacillus, Burkholde-
ria, Closteridium, Klebsiella, Pseudomonas aerogenosa,a n d
Serratia. Other bacteria that are known to be potentially
pathogenic to humans and detected using the metagenomic
technology were Campylobacter, Enterococcus, Proteus,a n d
Staphylococcus [113].
Reported also in 2010 were the results of an investigation
of the diversities of unaged and ﬂue-cured tobacco leaves
using a 16SrRNA sequence analysis scheme [43].
Others have reported the identiﬁcation of potentially
pathogenic bacteria in commercial cigarettes. One study was
undertaken to assess the bacterial diversity of cigarettes that
were thought to be linked to severe pneumonitis in US mil-
itary personnel deployed in Operation Iraqi Freedom [38].
Eight species of Bacillus, including ﬁve new species, and one
new species of Kurthia were isolated from the cigarettes.
Some of these species have been identiﬁed elsewhere to
cause hypersensitivity pneumonitis and other respiratory
syndromes [38]. This study was of particular interest to
many because the cigarettes were made in Iraq and not man-
ufactured by a major tobacco company. Undertaking this8 Journal of Oncology
investigation, the question arose as to whether the cigarettes
that had been purchased by soldiers from street vendors
had been intentionally altered by adding pathogenic bacteria
and/or mold. This theory was disproven.
Another study was conducted by a group of investigators
in Sweden who characterized the bacterial and fungal com-
munity in warehouse tobacco [41].
We have reported previously the establishment of a novel
bioassay which showed that bacteria were grown routinely
from a single ﬂake of tobacco that had been placed on the
surface of a sheep blood agar plate [42]. Of eight popular
brands of cigarettes, bacteria grew from almost all (>90%)
of the ﬂakes. Similarly, bacteria were grown from a single
ﬂake, and also with a high frequency, from tobacco that
had been retrieved from cigar ﬁller and from smokeless
tobacco (snus, snuﬀ, and long cut). Some bacteria induced
hemolysis of the blood in the agar dishes. The destruction
of the red blood cells was readily visible as a yellow
zone surrounding a single tobacco ﬂake. Expanding studies
documented the hemolysis of human blood in agar or
nutrient broth cultures. Thus, as discussed later, bacteria
could be carried deep into the respiratory tract by a single
tobacco ﬂake sucked from the cut surface of a cigarette ﬁlter
and transported into the bolus of smoke that is inhaled
deep into the lung. A single tobacco ﬂake may be envisioned
as a matrix for delivering diverse bacteria into the respira-
tory tract of an immunologically compromised long-term
smoker.
13.CigaretteswithMold
Mold has been identiﬁed in the tobacco of popular brand
cigarettes, and concern has been raised as to the propensity
of these microbes as a health risk to the smoker. Presented
herein is a partial listing of papers that have identiﬁed mold
in cigarettes [78, 114–116]a n di nm a r i j u a n a[ 116].
As early as 1971, Papavassiliou and coworkers concluded
that “[C]igarettes are contaminated with various fungi.”
They studied cigarettes that were manufactured in the USA,
Canada, England, France, Belgium, Germany, Jordan, and
Egypt. Hundreds of strains of fungi were isolated. The Greek
scientists demonstrate that the most prominent fungi were
Aspergillus (28 strains from Greek cigarettes and 35 strains
from other countries). They raised the question as of the
association of the fungi with allergies but commented that
this issue has not been resolved [114].
In1983,Kurupandcolleaguesreported theidentiﬁcation
of allergenic fungi in smoking materials and discussed the
healthimplications oftheirﬁndings [115].Concernhasbeen
expressed as to the health risks associated with mold in
cigarettes.
Writing in the Journal of the American Medical Associ-
ation, Verweij et al. addressed the propensity of heath risks
associated with fungal contaminates of tobacco and mar-
ijuana [116]. They concluded that “[A]ll cigarette brands
tested (N = 14brands) had some degree of fungal contam-
ination, although not every cigarette was found to have a
positive culture.”
14.Transferof TobaccoFlaketo
Mainstream Smoke
The ﬁlter of a cigarette is often contaminated with loose
tobacco ﬂakes, tobacco ﬁnes, and tobacco dust. In one exam-
ination,theﬁltersof11brandsofcigaretteswereexaminedin
freshly openedpacks.Forallbrands,cigaretteswereobserved
with tobacco ﬂakes on the ﬁlter. Examination of the ﬁlters
with the naked eye showed that 127 of 208 (61.1%) of the
ﬁlter had tobacco particles [42]. The release of tobacco ﬂakes
into mainstream smoke has been described previously [21,
22].
The tobacco ﬂakes that contaminate the ﬁlter arise from
tobacco that escapes from the nonﬁlter, sometimes called the
distal,endofthecigarette.Mostprobablytheﬂakesarejarred
looseduringmanufacturing, shipment,anddailytransporta-
tion, especially in a pack in which more than one-half of the
cigarettes have been used [117, 118].
The release of ﬂakes from the cut surface can readily be
demonstrated by comparing the cut surface of the ﬁlter be-
fore and after smoking the ﬁrst puﬀ.T h es i n g l eﬂ a k em a yb e
viewed as a matrix for carrying bacterial and fungal agents in
mainstream tobaccosmoke.Thus,theburningofthetobacco
during cigarette smoking does not exclude the exposure to
tobacco-associated microbes and microbial toxins.
Bacteria are also released from the barrel of the cigarette.
This was demonstrated in investigations in which a cigarette
was rolled over the surface of a nutrient agar dish.
15.Endotoxin(LPS)inMainstreamand
SidestreamTobaccoSmoke
In 1999, Hasday and his colleagues reported the identiﬁ-
cation of bacterial endotoxin as an active component in
cigarette tobacco and cigarette smoke [34]. The authors
showed that the dose of LPS delivered from smoking one
pack of cigarettes was comparable to that of the LPS that
had been previously shown to be associated with adverse
health eﬀects in cotton textile workers. With the knowledge
that LPS is one of the most potent inﬂammation-inducing
agents, the work by Hasday attracted considerable attention,
reviewed in [32]. In 2004, Larsson et al. reported that they
were able to demonstrate unequivocally that high levels of
LPS are inhaled during active cigarette smoking and, more
importantly, that environmental tobacco smoke may involve
inhalation of amounts of endotoxin that are dramatically
greater than those existing in indoor environments free
from tobacco smoke [36]. In 2006, these ﬁndings were
conﬁrmed and extended [39]. Particularly notable is that
studies of Larsson and colleagues used a mass-spectrometry-
based assay that circumvents the problems often associated
with the biologically based LPS assay.
16.Analysis ofFindingsand Policy
Recommendations
The resultsofthisliteraturereviewhavedocumentedthatthe
tobacco microﬂora has been the subject of many studies byJournal of Oncology 9
investigatorsoftobaccoindustryandacademiccommunities.
During the last 50 years, there has been an imbalance,
however, in the attention devoted to addressing the identiﬁ-
cation and propensity of the harm of tobacco- and tobacco-
smoke-associated chemicals and in the attention devoted to
characterizing microbes and microbial-derived factors.
Ample information has accumulated to suggest that
microbes and microbial-derived factors may contribute to
the health risks of smoking and smokeless tobacco products.
Moreover,the microbesmay facilitatemicrobial colonization
of the mouth and airway, the induction of chronic inﬂam-
mation through the activation of diverse leukocyte subsets,
alteration of the tissue microenvironment, and microbial-
toxin-induced pathologies. The current health concerns
recently expressed by investigators ofvarious disciplines, and
with diﬀerent research interests, in peer-reviewed published
research articles are reasonable and validate that additional
investigation of the microbiology of tobacco is warranted.
The ﬁndings reported herein relate to National Tobacco
Control Policy and speciﬁcally FDA Regulation of Tobacco
Products [119].
Based upon the information obtained in this paper, we
recommendthefollowingforconsiderationandpossiblereg-
ulatory action.
(1) Tobacco productsshould be assessed with the knowl-
edge that they contain bacteria, mold, and microbial
toxins.
(a) Inthiscontext,thedesignationoftobaccoprod-
ucts is to include conventional and novel
products that contain tobacco, including items
which are smoking and smokeless tobacco
articles.
(b) National and international registries of known
human carcinogens should not be used as the
sole criteria for assessing tobacco-associated
human health risks. Any and all tobacco-asso-
ciated agents that induce any human pathology
should be included in risk assessments.
(c) Tobacco in smoking and smokeless tobacco ar-
ticles should be assessed for their propensity
to induce chronic inﬂammation. Chronic in-
ﬂammation is known to be induced by diverse
bacteria (Gram positive and Gram negative)
and fungi, living or dead, whole or fragmented,
and intracellular and membrane components.
Chronic inﬂammation is known also to be in-
duced by diverse toxins of bacteria and/or fungi
including, but not limited to, endotoxins, exo-
toxins, and mycotoxins.
(d) Chronic inﬂammation associated with bacteria,
fungi, and microbial toxins of tobacco products
should include inﬂammation of any and all tar-
get sites, including tissues of the mouth, naso-
pharynx, and lung.
(e) In addition to chronic inﬂammation, harm
of microbial elements of tobacco should be
assessed in the context of other known tobacco-
associated diseases, including chronic obstruc-
tive pulmonary disease, asthma, bronchitis, and
alveolar hypersensitivity.
(2) Tobacco-speciﬁc nitrosamines (NNK) are human
carcinogens that are present in mainstream smoke,
sidestream smoke, and smokeless products. NNKs
arise primarily from the microbial degradation of
nicotine in tobacco. Diﬀerent technologies have
proven eﬀective in preventing the formation of
NNKs. It is recommended that these technologies be
implemented and that guidelines for tobacco articles
be established for reduced NNK-products.
(3) The criteria, protocols, and procedures used by the
FDA in the assessment of harm associated with my-
cotoxins in food products should be applied to
loose leaf tobacco, smoking tobacco products, and
smokeless tobacco articles. Mycotoxin action levels
should be established to provide an adequate margin
of safety to protect human tobacco users.
Abbreviations
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